LAB
Standard Biotools Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$3.1M | Q1 2026 | — |
|
|
|||
| Consumables revenue | $36.2M | full year 2025 | — |
| Gross margin | 49.9% | full year 2025 | — |
| Instruments revenue | $25.4M | full year 2025 | — |
| Non-GAAP gross margin non-GAAP | 53.6% | full year 2025 | — |
| Non-GAAP operating expenses non-GAAP | $27.8M | the fourth quarter of 2025 | — |
| Services revenue | $23.7M | full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LAB
this stock
Standard Biotools Inc.
|
$331.09M | -33.6% | -2.4% | 4.2 | 0.9% |
|
ABT
Abbott Laboratories
|
$160.44B | -26.1% | +5.7% | 25.8 | 1.3% |
|
SYK
Stryker Corp
|
$127.06B | -5.4% | +11.2% | 38.4 | 1.8% |
|
MDT
Medtronic plc
|
$106.97B | -12.3% | +8.4% | 22.4 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.37B | -53.2% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LAB | -4.5% | -6.6% | -45.5% | +3.7% | -33.6% |
| SPY | -0.3% | +1.6% | +8.3% | +0.3% | +9.9% |
| vs SPY | -4.2% | -8.1% | -53.8% | +3.3% | -43.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.